Investing.com - Moleculin Biotech (NASDAQ: MBRX) reported first quarter EPS of $-0.280, better than the analyst estimate of $-0.290. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Moleculin Biotech's stock price closed at $0.780. It is down -33.440% in the last 3 months and down -36.050% in the last 12 months.
Moleculin Biotech saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Moleculin Biotech's stock price’s past reactions to earnings here.
According to InvestingPro, Moleculin Biotech's Financial Health score is "weak performance".
Check out Moleculin Biotech's recent earnings performance, and Moleculin Biotech's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar